Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tissue Regenix Group has a Cash Ratio of 0.14. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Tissue Regenix Group's Cash Ratio or its related term are showing as below:
FRA:LSW'
s Cash Ratio Range Over the Past 10 Years
Min: 0.14 Med: 2.14 Max: 40.06
Current: 0.14
During the past 13 years, Tissue Regenix Group's highest Cash Ratio was 40.06. The lowest was 0.14. And the median was 2.14.
FRA:LSW's Cash Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.95
vs FRA:LSW: 0.14
Tissue Regenix Group (FRA:LSW) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Tissue Regenix Group Cash Ratio Related Terms
Tissue Regenix Group Cash Ratio Historical Data
* Premium members only.
The historical data trend for Tissue Regenix Group's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LSW vs VRTX, REGN, ALNY: Cash Ratio Comparison
For the Biotechnology subindustry, Tissue Regenix Group's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tissue Regenix Group Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Tissue Regenix Group's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tissue Regenix Group (FRA:LSW) has a Cash Ratio of 0.14 as of Jun. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Tissue Regenix Group and its competitors. This is 93% below median its historical median of 2.14. Over the past decade, Tissue Regenix Group's Cash Ratio has ranged from 0.14 to 40.06.
Is Tissue Regenix Group's Cash Ratio too high?
Tissue Regenix Group's current Cash Ratio of 0.14 is 93% below median its 10-year median of 2.14. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 40.06. The Biotechnology industry median Cash Ratio is 2.95. Tissue Regenix Group's value of 0.14 is 95.3% below this industry median. Overall, Tissue Regenix Group has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Tissue Regenix Group's Cash Ratio compare to VRTX and REGN?
Tissue Regenix Group's Cash Ratio of 0.14 can be compared against companies in the Biotechnology industry. The industry median Cash Ratio is 2.95. Tissue Regenix Group's value of 0.14 is 95.3% below this benchmark. Historically, Tissue Regenix Group's own Cash Ratio has ranged from 0.14 to 40.06 over the past decade. While the company's 10-year median is 2.14 vs. the industry median of 2.95, Tissue Regenix Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tissue Regenix Group's current Cash Ratio of 0.14 is 95.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Tissue Regenix Group and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tissue Regenix Group's current Cash Ratio is 0.14, which is 93% below median its own 10-year median of 2.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (FRA:LSW) has a current Cash Ratio of 0.14. The stock's GF Value™ is €0.84, compared to a current price of €0.07 — trading 91.7% below its estimated fair value. The current Cash Ratio is 0.14, which is 93% below median its 10-year median of 2.14 and 95.3% below the Biotechnology industry median of 2.95. Tissue Regenix Group's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Tissue Regenix Group (FRA:LSW), the current Cash Ratio is 0.14 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tissue Regenix Group (FRA:LSW) Overvalued in 2026?
Based on GuruFocus' analysis, Tissue Regenix Group stock appears to be undervalued.
The current stock price of €0.07 is trading 91.7% below its estimated GF Value™ of €0.84.
Key valuation signals for FRA:LSW:
Cash Ratio: 0.14 (93% below median its 10-year median of 2.14)
GF Value™: €0.84 vs. price of €0.07 (91.7% below fair value)
Industry Position: 95.3% below the Biotechnology median
No single metric tells the full story. See the FRA:LSW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.
10GF Score
Get the complete analysis for FRA:LSW
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LSW has been successfully added to your 
